Illustration of radiofrequency ablation targeting liver tumors from gastric cancer.

Gastric Cancer Breakthrough: New Hope for Liver Metastasis Treatment

Jordan Keane monogram
Jordan Keane in Health & Wellness November 2026 • 5 min read.

"Groundbreaking Study Reveals Radiofrequency Ablation as a Promising Solution for Patients with Metastatic Liver Tumors of Gastric Origin"


Gastric cancer, a formidable adversary in the realm of oncology, frequently presents challenges that extend beyond its primary site. One of the most concerning complications is the spread of cancer cells to the liver, leading to metastatic liver tumors. This metastasis significantly impacts patient prognosis, underscoring the need for effective and innovative treatment strategies. Traditionally, managing liver metastases from gastric cancer has been complex, often involving systemic chemotherapy, which can have limited success and significant side effects.

However, a recent clinical trial has introduced a beacon of hope in the form of radiofrequency ablation (RFA). This minimally invasive procedure, which uses heat to destroy cancer cells, is showing promising results in the treatment of metastatic liver tumors originating from gastric cancer. This article delves into the specifics of the study, its findings, and what it means for patients and healthcare professionals alike. We will explore the details of the study and its implications for the future of cancer treatment.

This study marks a pivotal advancement in cancer treatment, offering a novel approach that could significantly improve outcomes for patients battling metastatic liver tumors of gastric origin. As we explore the details, we will highlight the potential of RFA and its role in the fight against cancer.

AI Search Multiple angles on this topic

A Significant Treatment Challenge

Liver metastasis represents a serious complication of gastric cancer and can substantially limit treatment options. Its impact varies with disease extent, tumor location, patient health, and whether local treatment is feasible. Because the available evidence is heterogeneous, treatment decisions generally require individualized assessment rather than a single standard strategy.

Resection and Radiofrequency Ablation

Liver resection and radiofrequency ablation (RFA), often considered alongside chemotherapy, are established liver-directed approaches for gastric-cancer metastases, but optimal management remains controversial. Image-guided percutaneous RFA is described as a viable option for unresectable gastrointestinal liver metastases, with optimized technology and adequate safety margins producing oncologic results comparable to surgery in selected cases. Its use for resectable metastases remains debated, and feasibility and success depend partly on tumor size and achieving sufficient treatment margins. Retrospective studies have specifically compared RFA with liver resection and chemotherapy, including an evaluation of 50 patients after curative gastrectomy.

From Early Ablation to Modern RFA

Historical reviews indicate that several ablation methods emerged mainly in the late 20th century, although at least one method dates to the 19th century. Radiofrequency ablation uses medium-frequency alternating current, reported in the range of 350 kHz to 1 MHz, to generate heat and selectively destroy dysfunctional tissue, including tumors. A history of the technology reports that the first radiofrequency ablation device came to market from Aronow and Cosman roughly 30 years after early development. By 2006, RFA had also been introduced for thyroid nodules and reported as effective and safe for recurrent thyroid cancer and benign thyroid nodules.

Understanding the Study: A Deeper Dive into the Research

Illustration of radiofrequency ablation targeting liver tumors from gastric cancer.

The clinical trial, designed to evaluate the efficacy of radiofrequency ablation (RFA) in treating metastatic liver tumors from gastric cancer, followed a randomized clinical design. The study included 43 patients who were diagnosed with metastatic lesions in the liver, originating from gastric cancer. Patients were carefully selected, ensuring that the number of liver lesions was less than five and that the size of the lesions was smaller than five centimeters. This rigorous selection process was crucial to ensure the integrity and validity of the study's findings.

The patients were divided into two groups. Group A received chemotherapy combined with RFA, while Group B received chemotherapy alone. The effectiveness of the treatments was then evaluated by assessing changes in tumor size and contrast enhancement using Magnetic Resonance Imaging (MRI). The outcomes of this comparative analysis provided crucial insights into the efficacy of RFA in combination with chemotherapy. This methodology allowed researchers to measure the impact of RFA by observing changes in tumor size and how the tumors responded to the contrast enhancement in MRI scans.

  • Patient Demographics: The study included 26 males and 17 females. The mean age of the participants was 62.51 ± 12.12 years.
  • No Significant Differences: The study found no significant difference in age or gender distribution between the two groups, ensuring a balanced comparison.
  • Lesion Location: In 93.02% of patients, the metastasis was found in the right hepatic lobe, a common site for such tumors.
  • Tumor Size: The average size of metastases was similar in both groups at the start of the study, with 2.96 ± 1.14 cm in Group A and 3.01 ± 0.96 cm in Group B.
  • Treatment Outcomes: Patients in Group A (RFA + chemotherapy) showed significantly better results, with 66.6% achieving complete lesion clearance compared to Group B.
  • Treatment Response: The study showed that lesions smaller than 3 cm in Group A responded better to treatment.
AI Search Multiple angles on this topic

An Evolving Evidence Base

Recent research on gastric-cancer liver metastasis continues to examine how local treatments such as radiofrequency ablation may fit into broader care. The evidence appears to remain developing, with ongoing attention to patient selection, treatment technique, and long-term outcomes. These findings support cautious optimism, but they do not establish RFA as universally superior to surgery or systemic treatment.

Complications and Patient Selection

RFA is intended for appropriately selected patients, particularly those who cannot undergo liver resection, and its hoped-for survival benefit depends on correct use. Reported complications include a range of procedure-related problems, making risk assessment and technical execution important. A 2024 review discusses complication risk factors and strategies intended to minimize them and achieve complete tumor ablation. Earlier reviews likewise emphasize that RFA feasibility and success depend on factors such as adequate margins and appropriate case selection.

RFA Versus Hepatic Resection

A study from Seoul St. Mary’s Hospital compared RFA with hepatic resection in 18 patients who had liver metastases alone from gastric cancer. The cohort included 11 patients treated with RFA and 7 treated with hepatic resection between January 2000 and September 2014. Because this was a small retrospective series, its results should be interpreted as comparative clinical evidence rather than definitive proof that one treatment is superior. The listed comparison sources also address RFA and other endoscopic therapies for gastric low-grade intraepithelial neoplasia, which is a different clinical setting from liver metastasis.

The results of the study provide strong evidence of RFA's potential as a significant treatment option for metastatic liver tumors originating from gastric cancer. The data shows that RFA, when used in conjunction with chemotherapy, offers a superior outcome compared to chemotherapy alone. The study's findings represent a major step forward in cancer treatment, offering new hope and improved prospects for patients with this challenging condition.

Looking Ahead: The Future of Gastric Cancer Treatment

The results of this clinical trial are a promising step forward in the treatment of metastatic liver tumors originating from gastric cancer. The findings emphasize the effectiveness of RFA in combination with chemotherapy, highlighting the potential of this minimally invasive procedure. As research continues, the integration of RFA into standard treatment protocols may provide a significant improvement in patient outcomes. The study underscores the importance of ongoing research and innovation in the field of oncology, offering hope for a future where cancer treatment is more effective and less invasive. The study's findings mark an important advance, opening new avenues for patient care and treatment strategies, contributing to improved survival rates and enhanced quality of life for individuals battling this challenging disease.

AI Search Multiple angles on this topic

A Selective Role for RFA

Recent studies are exploring RFA in several gastric and gastrointestinal contexts, but their conclusions are not interchangeable. One 2025 study examined RFA for high-risk gastric intestinal metaplasia, while another described RFA as effective for low-grade gastric dysplasia but not the preferred treatment for high-grade gastric dysplasia. A separate study investigated secondary ultrasound-guided RFA for patients with gastric cancer and liver metastasis, reflecting interest in repeat or combined local treatment. Together, these reports suggest expanding investigation rather than a single settled indication.

Growth and Technology Development

Market-oriented sources project continued expansion of ablation technologies and endoscopic RFA applications. One forecast values the endoscope RFA market at USD 392 million in 2025 and projects USD 1.22 billion by 2035. Another describes endoscopic RFA as a minimally invasive technique using controlled heat to treat conditions including Barrett’s esophagus and early-stage cancer. A separate forecast places the global tumor-ablation market at USD 846.8 million in 2025, rising to USD 1.5797 billion by 2034, although these commercial projections do not by themselves establish clinical benefit for gastric-cancer liver metastases.

Complexity Beyond the Procedure

The broader challenge is determining which patients are most likely to benefit from local treatment while managing the risks of disease progression and procedural complications. Decisions may be influenced by tumor burden, technical feasibility, prior treatment, and the availability of specialist expertise. As evidence continues to develop, access to careful staging, multidisciplinary evaluation, and follow-up remains important.

Patient Outcomes in Practice

A retrospective study analyzed the clinical profiles and follow-up information of 137 patients with gastrointestinal-cancer liver metastases to investigate how RFA affected prognosis. The study was motivated by recent retrospective reports suggesting that RFA may improve survival outcomes in some patients. Its aim was to provide insight into optimizing treatment, but retrospective findings cannot by themselves prove that RFA caused better survival. The results therefore highlight potential patient benefit while supporting the need for careful selection and further confirmation.

Survival figures reported after RFA

  • 20.9; 9.8 monthsFor patients with liver-only metastases treated with RFA and systemic chemotherapy, reported overall survival was 20.9 months and recurrence-free survival was 9.8 months. These figures describe a combined-treatment group, not RFA alone.[1]

What survival outcomes can-and cannot-tell us

The reported survival outcomes show that some patients lived for months after liver-directed ablation, but they do not by themselves establish that ablation caused longer survival. The reports describe different patient groups and treatment combinations, and the available figures are not a controlled comparison.[1] [2] [3]

The pooled survival estimates apply to thermal ablation in patients without peritoneal disease; they should not be read as a prediction for every patient with gastric cancer liver metastases. The evidence also leaves unresolved which patients benefit from RFA compared with liver resection.[3] [4]

How RFA evidence compares across settings

A small early report described RFA as a possible alternative for gastric adenocarcinoma liver metastasis, while noting its limited case count and short follow-up. Later evidence still identifies a shortage of prospective trials with long-term outcomes and uncertainty about who benefits from RFA or hepatic resection.[4] [5]

Technical context helps explain why lesion size and treatment margins matter: a review describes lesions under 3 cm as ideal for RFA to achieve a tumor-free margin, while also noting that larger metastases have been treated. The aim of curative ablation is to destroy all tumor cells with an adequate margin while limiting damage to nearby tissue.[3] [6]

Sources

  1. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer (pmc.ncbi.nlm.nih.gov)
  2. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. (pubmed.ncbi.nlm.nih.gov)
  3. Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long-term survival (pmc.ncbi.nlm.nih.gov)
  4. Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection - PMC Lock (pmc.ncbi.nlm.nih.gov)
  5. Radiofrequency Ablation for Hepatic Metastasis from Gastric Adenocarcinoma (pmc.ncbi.nlm.nih.gov)
  6. Advanced Techniques in the Percutaneous Ablation of Liver Tumours (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1093/annonc/mdu334.53, Alternate LINK

Title: Efficacy Of Radiofrequency Ablation In Metastatic Liver Tumors With Gastric Origin

Subject: Oncology

Journal: Annals of Oncology

Publisher: Elsevier BV

Authors: G. Janbabai, H. Shahabandaz, Y. Sakhaei, R. Abdi, M. Teimourzadeh, S. Borhani

Published: 2014-09-01

Everything You Need To Know

1

What is radiofrequency ablation (RFA) and how does it help in treating liver metastasis from gastric cancer?

Radiofrequency ablation (RFA) is a minimally invasive procedure that uses heat to destroy cancer cells. In the context of liver metastasis stemming from gastric cancer, RFA is used to target and ablate metastatic liver tumors. The study showed that RFA, when combined with chemotherapy, offers better outcomes compared to chemotherapy alone, particularly for lesions smaller than 3 cm. While RFA directly addresses the liver tumors, it's important to note that it doesn't prevent new metastases from forming. Systemic treatments like chemotherapy are still needed to manage the spread of cancer cells throughout the body.

2

What were the key findings of the clinical trial regarding the use of radiofrequency ablation (RFA) for metastatic liver tumors from gastric cancer?

The clinical trial demonstrated that patients with metastatic liver tumors originating from gastric cancer who received radiofrequency ablation (RFA) in combination with chemotherapy (Group A) showed significantly better results compared to those who received chemotherapy alone (Group B). Specifically, 66.6% of patients in Group A achieved complete lesion clearance. The study also indicated that lesions smaller than 3 cm in Group A responded better to treatment. These findings suggest that RFA is a promising treatment option for these types of tumors, however the study only included patients with less than 5 lesions smaller than 5 centimeters.

3

How was the study designed to evaluate the effectiveness of radiofrequency ablation (RFA) in treating metastatic liver tumors from gastric cancer?

The clinical trial used a randomized clinical design, involving 43 patients diagnosed with metastatic liver lesions originating from gastric cancer. These patients had less than five liver lesions, each smaller than five centimeters. The patients were divided into two groups: Group A, which received chemotherapy combined with radiofrequency ablation (RFA), and Group B, which received chemotherapy alone. The effectiveness of each treatment was assessed by monitoring changes in tumor size and contrast enhancement using Magnetic Resonance Imaging (MRI). This comparative analysis provided insights into how RFA, combined with chemotherapy, impacts metastatic liver tumors.

4

What are the implications of using radiofrequency ablation (RFA) combined with chemotherapy for patients with metastatic liver tumors from gastric cancer, especially considering lesion size and location?

The implications of using radiofrequency ablation (RFA) combined with chemotherapy are significant for patients with metastatic liver tumors from gastric cancer. The study indicates that this combination can lead to better outcomes, particularly complete lesion clearance, improving the chances of survival and quality of life. Specifically, lesions smaller than 3 cm respond more favorably to the treatment. The study also noted that most metastases were located in the right hepatic lobe, which suggests that RFA is effective in treating tumors in this specific location. However, the study focused on patients with a limited number of lesions and a specific size, future treatments and studies must consider all cancer patient profiles.

5

What are the next steps or future research directions that could build upon the findings of this clinical trial regarding radiofrequency ablation (RFA) and metastatic liver tumors from gastric cancer?

Building on the findings of this clinical trial, future research could explore several avenues to enhance the use of radiofrequency ablation (RFA) for metastatic liver tumors from gastric cancer. Studies could investigate the long-term survival rates and recurrence patterns in patients treated with RFA plus chemotherapy compared to other treatments. Research could also focus on identifying which patients are most likely to benefit from RFA based on factors like genetic markers, tumor characteristics, and overall health. Additionally, studies could explore combining RFA with other novel therapies, such as immunotherapy or targeted agents, to further improve treatment outcomes. It would also be useful to investigate if the location of metastasis affects the success of the RFA. Finally, future studies should aim to expand the inclusion criteria to involve patients with multiple lesions larger than the current study limits, to assess a boarder scope of patients.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.